CAR T cells ease severe arthritis in first clinical trial

A PET-MRI image of a participant's knee shows the change in place: inflammatory activity visible before treatment was no longer detectable several months after the infusion. At Charité—Universitätsmedizin Berlin, six patients with particularly severe, treatment-refractory rheumatoid arthritis received CD19 CAR T-cell therapy, and disease activity decreased in all of them.

The treatment borrows a cancer tool for a different immune-system problem. Doctors collected each patient's T cells — immune cells that normally identify infected or abnormal cells — and modified them in the laboratory with a chimeric antigen receptor, or CAR. This receptor acts as a search sensor for CD19, a surface marker on many B cells. After a short course of preparatory chemotherapy, the modified cells were returned in a single infusion to seek out CD19-positive cells.

The target is not simply inflammation. Researchers David Simon and Gerhard Krönke suspect that disease-driving B cells can persist in lymph nodes, bone marrow and joint tissue, producing harmful antibodies and reigniting attacks on the body's own joints. In the study, the CAR T cells appeared to eliminate these deeper B-cell reservoirs as well as temporarily removing CD19-positive B cells elsewhere, an approach intended to reset the pathological immune memory.

The result is notable in patients whose disease had not responded sufficiently to several treatments: three patients were in sustained remission without rheumatoid arthritis medication during follow-up of up to one year. Swelling and pain subsided, and mobility improved. Existing treatments can usually control rheumatoid arthritis but do not cure it, leaving many patients dependent on lifelong medication; this therapy could offer a different path for the small group whose disease remains refractory.

The limits are just as concrete. This is the phase 1 part of the ongoing phase 1/2 COMPARE trial, involving six patients aged 31–69 who had already tried up to eight targeted or biologic therapies over 10 years. Nature Medicine reported clinical improvement in all patients and good tolerability, but the evidence is still based on a small early-stage trial rather than established routine care.